Ribociclib-induced vitiligo in a case of metastatic carcinoma of the breast
Ribociclib, a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, is commonly used to treat hormone receptor-positive (HR+), human epidermal growth factor receptor 2/neu negative (HER2/neu-) breast cancer. While effective in inhibiting cancer cell proliferation, ribociclib has been associated with vario...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2025-01-01
|
| Series: | Journal of the Egyptian Women’s Dermatologic Society |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/jewd.jewd_64_24 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832594164755202048 |
|---|---|
| author | Abhira Deb Manthan Dhingra Srutee Barman Thinakaran Raja Abhra Ghosh |
| author_facet | Abhira Deb Manthan Dhingra Srutee Barman Thinakaran Raja Abhra Ghosh |
| author_sort | Abhira Deb |
| collection | DOAJ |
| description | Ribociclib, a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, is commonly used to treat hormone receptor-positive (HR+), human epidermal growth factor receptor 2/neu negative (HER2/neu-) breast cancer. While effective in inhibiting cancer cell proliferation, ribociclib has been associated with various dermatologic side effects, including vitiligo. This condition, characterized by the loss of skin pigmentation, occurs due to the destruction of melanocytes. In breast cancer patients undergoing ribociclib therapy, though the exact pathophysiological mechanisms remain under investigation, a possible hypothesis suggests that the development of vitiligo may signal an immune-mediated response, potentially reflecting the drug’s influence on immune modulation. This report presents a case of HR+ and HER2/neu− metastatic breast carcinoma treated with CDK4/6 inhibitor plus endocrine therapy with the development of vitiligo during the treatment. |
| format | Article |
| id | doaj-art-b0a82198fc7a424c817ee5e2c08c9e35 |
| institution | Kabale University |
| issn | 2090-2565 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Journal of the Egyptian Women’s Dermatologic Society |
| spelling | doaj-art-b0a82198fc7a424c817ee5e2c08c9e352025-01-20T04:39:19ZengWolters Kluwer Medknow PublicationsJournal of the Egyptian Women’s Dermatologic Society2090-25652025-01-01221889110.4103/jewd.jewd_64_24Ribociclib-induced vitiligo in a case of metastatic carcinoma of the breastAbhira DebManthan DhingraSrutee BarmanThinakaran RajaAbhra GhoshRibociclib, a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, is commonly used to treat hormone receptor-positive (HR+), human epidermal growth factor receptor 2/neu negative (HER2/neu-) breast cancer. While effective in inhibiting cancer cell proliferation, ribociclib has been associated with various dermatologic side effects, including vitiligo. This condition, characterized by the loss of skin pigmentation, occurs due to the destruction of melanocytes. In breast cancer patients undergoing ribociclib therapy, though the exact pathophysiological mechanisms remain under investigation, a possible hypothesis suggests that the development of vitiligo may signal an immune-mediated response, potentially reflecting the drug’s influence on immune modulation. This report presents a case of HR+ and HER2/neu− metastatic breast carcinoma treated with CDK4/6 inhibitor plus endocrine therapy with the development of vitiligo during the treatment.https://journals.lww.com/10.4103/jewd.jewd_64_24breast cancercyclin-dependent kinase 4/6 inhibitorsribociclibvitiligo |
| spellingShingle | Abhira Deb Manthan Dhingra Srutee Barman Thinakaran Raja Abhra Ghosh Ribociclib-induced vitiligo in a case of metastatic carcinoma of the breast Journal of the Egyptian Women’s Dermatologic Society breast cancer cyclin-dependent kinase 4/6 inhibitors ribociclib vitiligo |
| title | Ribociclib-induced vitiligo in a case of metastatic carcinoma of the breast |
| title_full | Ribociclib-induced vitiligo in a case of metastatic carcinoma of the breast |
| title_fullStr | Ribociclib-induced vitiligo in a case of metastatic carcinoma of the breast |
| title_full_unstemmed | Ribociclib-induced vitiligo in a case of metastatic carcinoma of the breast |
| title_short | Ribociclib-induced vitiligo in a case of metastatic carcinoma of the breast |
| title_sort | ribociclib induced vitiligo in a case of metastatic carcinoma of the breast |
| topic | breast cancer cyclin-dependent kinase 4/6 inhibitors ribociclib vitiligo |
| url | https://journals.lww.com/10.4103/jewd.jewd_64_24 |
| work_keys_str_mv | AT abhiradeb ribociclibinducedvitiligoinacaseofmetastaticcarcinomaofthebreast AT manthandhingra ribociclibinducedvitiligoinacaseofmetastaticcarcinomaofthebreast AT sruteebarman ribociclibinducedvitiligoinacaseofmetastaticcarcinomaofthebreast AT thinakaranraja ribociclibinducedvitiligoinacaseofmetastaticcarcinomaofthebreast AT abhraghosh ribociclibinducedvitiligoinacaseofmetastaticcarcinomaofthebreast |